Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Maressa Bruhn
No relevant relationships to disclose
Chee Lee
No relevant relationships to disclose
Jenny Hardingham
Research Funding - Roche
Amanda Rose Townsend
No relevant relationships to disclose
Kristy Mann
No relevant relationships to disclose
John Simes
No relevant relationships to disclose
Andrew James Weickhardt
No relevant relationships to disclose
Joe Wrin
No relevant relationships to disclose
Kate Wilson
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Bridget Anne Robinson
No relevant relationships to disclose
Guy A. Van Hazel
No relevant relationships to disclose
David Cunningham
Research Funding - Roche
Niall C. Tebbutt
Consultant or Advisory Role - Roche (U)